US drug pharma Johnson and Johnson has joined hands with Telangana-based biopharmaceutical company Biological E for the manufacturing of their Janssen Covid-19 vaccine. The vaccine is currently approved in the US, Europe and other nations including Thailand and South Africa.
Biological E. will produce the Janssen vaccine alongside its own candidate vaccine, said Mahima Datla managing director of Biological E in a statement to Reuters. “The infrastructure and plants are completely separate for both the products and we will be producing both independent of each other,” she said.
J&J said that the company is in discussion with the Indian government to soon begin bridging trials for its single-dose Covid-19 vaccine candidate.
“We believe Biological E. will be an important part of our global COVID-19 vaccine supply network, where multiple manufacturing sites are involved in the production of our vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed,” an official statement by Johnson and Johnson said.
India has currently approved three vaccines that are in use- Covishied, Covaxin and Russia’s Sputnik V.